Mobile  |  About us  |  Photos  |  Videos  |  Subscriptions  |  RSS Feeds  |  Today's Paper  |  Classifieds  |  Contact Us
The Daily Star
MONDAY, 21 APR 2014
06:12 AM Beirut time
Weather    
Beirut
17 °C
Blom Index
BLOM
1,214.01down
Health
Follow this story Print RSS Feed ePaper share this
IPS Genomix and ‘Personalized Medicine in Oncology’
A symposium organized by IPS Genomix on the concept of Personalized Medicine in Oncology in September 2013.  (The Daily Star/HO)
A symposium organized by IPS Genomix on the concept of Personalized Medicine in Oncology in September 2013. (The Daily Star/HO)
A+ A-

Under the auspices of the Lebanese Association for Oncology, IPS Genomix has organized a symposium on the concept of Personalized Medicine in Oncology, hosted by Professor Fadlo Khuri, head of hematology – oncology section at Emory University and vice president of Winship Cancer Institute-USA.

First, the IPS (Integrated Pharma Solutions) Group CEO, Ahmed Yacout, talked about the interest given by the company to Personalized Medicine in Oncology.

The president of the Lebanese Society of Medical Oncology and chairman of the hematology-oncology department at Hotel Dieu de France University hospital, Professor George Chahine, has inaugurated the symposium.

A session has been dedicated to discussing and answering the questions of the participants, and was shared by the head of the hematology-oncology division at AUBMC, Professor Ali Shamseddine.

The participants followed with great interest the presentation of Professor Khuri that comprised the development stages of Personalized Medicine in Oncology, since “the existing scientific revolution in the fields of medicine and genetic researches has engendered a positive development in the quality of health care provided to cancer patients.

The idea of personalized medicine is not new. However, nowadays, with the technique of detailed genetic tests, a more precise and efficient personalized treatment is possible to eradicate the cancerous tumor, with less side effects on the patient.”

He added: “We are at a time when the cost of treating cancer is high, whether it is a chemical treatment or a targeted therapy. Now, and due to genetic tests, we are capable of knowing more details about the tumor, about each patient and the specificity of his case. This means that we are capable of obtaining better results, at a lower cost.”

 
Home Health
 
     
 
Lebanon
Advertisement
Comments  

Your feedback is important to us!

We invite all our readers to share with us their views and comments about this article.

Disclaimer: Comments submitted by third parties on this site are the sole responsibility of the individual(s) whose content is submitted. The Daily Star accepts no responsibility for the content of comment(s), including, without limitation, any error, omission or inaccuracy therein. Please note that your email address will NOT appear on the site.

comments powered by Disqus
Advertisement


Baabda 2014
Advertisement
Follow us on Facebook Follow us on Twitter Follow us on Linked In Follow us on Google+ Subscribe to our Live Feed
Multimedia
Images  
Pictures of the day
A selection of images from around the world- Saturday April 19, 2014
View all view all
Advertisement
Rami G. Khouri
Rami G. Khouri
Why Israeli-Palestinian talks fail
Michael Young
Michael Young
Why confuse gibberish with knowledge?
David Ignatius
David Ignatius
Echoes of 1914 characterize the Ukraine crisis
View all view all
Advertisement
cartoon
 
Click to View Articles
 
 
News
Business
Opinion
Sports
Culture
Technology
Entertainment
Privacy Policy | Anti-Spamming Policy | Disclaimer | Copyright Notice
© 2014 The Daily Star - All Rights Reserved - Designed and Developed By IDS